Company Overview of GlycoVaxyn AG
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
Founded in 2004
41 44 733 85 85
41 44 733 85 74
Key Executives for GlycoVaxyn AG
Similar Private Companies By Industry
|AB2 Bio Ltd.||Europe|
|ADC Products Switzerland SARL||Europe|
|ADC Therapeutics SA||Europe|
|AlloCyte Pharmaceuticals AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
To contact GlycoVaxyn AG, please visit www.glycovaxyn.com/. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.